Galera Therapeutics Q3 EPS $(0.33) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $28.4M Are Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2025
Galera Therapeutics Q3 EPS $(0.33) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $28.4M Are Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2025
Galera Therapeutics第三季度每股收益爲0.33美元，超過了美元（0.40美元）的預期；現金、現金等價物和2840萬美元的短期投資預計將在2025年之前爲其運營費用和資本支出需求提供資金
Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 45 percent increase over losses of $(0.60) per share from the same period last year.
Galera Therapeutics（納斯達克股票代碼：GRTX）公佈季度每股虧損0.33美元，比分析師普遍估計的0.40美元（0.40美元）高出17.5％。這比去年同期每股虧損美元（0.60美元）增加了45％。